ABIOMED (ABMD) : Palo Alto Investors reduced its stake in ABIOMED by 8.83% during the most recent quarter end. The investment management company now holds a total of 1,884,384 shares of ABIOMED which is valued at $207,301,084 after selling 182,535 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.ABIOMED makes up approximately 12.08% of Palo Alto Investors’s portfolio.
Other Hedge Funds, Including , Fmr added ABMD to its portfolio by purchasing 176,503 company shares during the most recent quarter which is valued at $19,417,095. Baird Financial Group added ABMD to its portfolio by purchasing 19,941 company shares during the most recent quarter which is valued at $2,138,672. ABIOMED makes up approx 0.02% of Baird Financial Group’s portfolio.Emerald Acquisition Ltd. boosted its stake in ABMD in the latest quarter, The investment management firm added 16,532 additional shares and now holds a total of 196,206 shares of ABIOMED which is valued at $20,801,760. ABIOMED makes up approx 0.04% of Emerald Acquisition Ltd.’s portfolio. Palladium Partners added ABMD to its portfolio by purchasing 1,689 company shares during the most recent quarter which is valued at $181,297. ABIOMED makes up approx 0.02% of Palladium Partners’s portfolio.Tirschwell Loewy Inc reduced its stake in ABMD by selling 375 shares or 0.45% in the most recent quarter. The Hedge Fund company now holds 82,425 shares of ABMD which is valued at $10,053,377. ABIOMED makes up approx 1.73% of Tirschwell Loewy Inc’s portfolio.
ABIOMED closed down -0.19 points or -0.17% at $113.41 with 8,17,781 shares getting traded on Monday. Post opening the session at $113.51, the shares hit an intraday low of $113.04 and an intraday high of $114.7 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, ABIOMED reported $0.20 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Oct 27, 2016. Analyst had a consensus of $0.25. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $103.12 million. The company’s revenue was up 35.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.